The bactericidal activity of ampicillin, daptomycin, and vancomycin against ampicillin-resistant Enterococcus faecium.

[1]  H. Fletcher,et al.  Emergence of isolates resistant to ampicillin. , 1989, American journal of diseases of children.

[2]  W. J. Tuddenham,et al.  Enterococci highly resistant to penicillin and ampicillin: an emerging clinical problem? , 1989, Journal of clinical microbiology.

[3]  M. Wendeler,et al.  High-level penicillin resistance among isolates of enterococci. Implications for treatment of enterococcal infections. , 1989, Annals of internal medicine.

[4]  M. Collins,et al.  Identification of Enterococcus species isolated from human infections by a conventional test scheme , 1989, Journal of clinical microbiology.

[5]  G. Eliopoulos,et al.  High-level resistance to gentamicin in clinical isolates of Streptococcus (Enterococcus) faecium , 1988, Antimicrobial Agents and Chemotherapy.

[6]  J. Duval,et al.  Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. , 1988, The New England journal of medicine.

[7]  S. Fischer,et al.  Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital , 1988, Journal of clinical microbiology.

[8]  L. Bush,et al.  Daptomycin (LY146032) treatment of experimental enterococcal endocarditis , 1988, Antimicrobial Agents and Chemotherapy.

[9]  A. Wanger,et al.  Activity of LY146032 against Enterococci with and without high-level aminoglycoside resistance, including two penicillinase-producing strains , 1987, Antimicrobial Agents and Chemotherapy.

[10]  T. Patterson,et al.  Activity of LY146032 in vitro and in experimental enterococcal pyelonephritis , 1987, Antimicrobial Agents and Chemotherapy.

[11]  C. Stratton,et al.  Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies , 1987, Antimicrobial Agents and Chemotherapy.

[12]  M. Zervos,et al.  Nosocomial infection by gentamicin-resistant Streptococcus faecalis. An epidemiologic study. , 1987, Annals of internal medicine.

[13]  M. Weiser,et al.  Identification of Streptococcus faecalis and Streptococcus faecium and susceptibility studies with newly developed antimicrobial agents , 1987, Journal of clinical microbiology.

[14]  R. Jones,et al.  Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations , 1987, Antimicrobial Agents and Chemotherapy.

[15]  L. Verbist.  In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci , 1987, Antimicrobial Agents and Chemotherapy.

[16]  A. Wanger,et al.  Comparison of two beta-lactamase-producing strains of Streptococcus faecalis , 1986, Antimicrobial Agents and Chemotherapy.

[17]  R. Fass,et al.  In vitro activity of LY146032 against staphylococci, streptococci, and enterococci , 1986, Antimicrobial Agents and Chemotherapy.

[18]  G. Eliopoulos,et al.  In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic , 1986, Antimicrobial Agents and Chemotherapy.

[19]  G. Satta,et al.  Transition from resistance to hypersusceptibility to beta-lactam antibiotics associated with loss of a low-affinity penicillin-binding protein in a Streptococcus faecium mutant highly resistant to penicillin , 1985, Antimicrobial Agents and Chemotherapy.

[20]  H. Koornhof,et al.  Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions , 1985, Antimicrobial Agents and Chemotherapy.

[21]  G. Eliopoulos,et al.  In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic , 1985, Antimicrobial Agents and Chemotherapy.

[22]  T. File,et al.  Timentin versus piperacillin or moxalactam in the therapy of acute bacterial infections , 1984, Antimicrobial Agents and Chemotherapy.

[23]  K. Crossley,et al.  Susceptibilities of enterococci to twelve antibiotics , 1984, Antimicrobial Agents and Chemotherapy.

[24]  B. Murray,et al.  High-level resistance to gentamicin in clinical isolates of enterococci. , 1983, The Journal of infectious diseases.

[25]  D. Krogstad,et al.  Antibiotic-induced lysis of enterococci. , 1981, The Journal of clinical investigation.

[26]  N. Georgopapadakou,et al.  Binding of beta-lactam antibiotics to penicillin-binding proteins of Staphylococcus aureus and Streptococcus faecalis: relation to antibacterial activity , 1980, Antimicrobial Agents and Chemotherapy.

[27]  D. Krogstad,et al.  Defective killing of enterococci: a common property of antimicrobial agents acting on the cell wall , 1980, Antimicrobial Agents and Chemotherapy.

[28]  M. Sande,et al.  Species-specific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis. , 1979, The Journal of infectious diseases.

[29]  C. Watanakunakorn.  Penicillin combined with gentamicin or streptomycin: synergism against enterococci. , 1971, The Journal of infectious diseases.

[30]  M. Finland,et al.  Susceptibility of Group D Streptococcus (Enterococcus) to 21 Antibiotics In Vitro, with Special Reference to Species Differences , 1969, The American journal of the medical sciences.

[31]  T. Hunter.  Use of streptomycin in the treatment of bacterial endocarditis. , 1947, The American journal of medicine.